ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,028 GBX | -2.18% |
|
-0.56% | +13.47% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
170.1
USD
Spread / Average Target
+10.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.47% | 243B | |
| +38.59% | 727B | |
| -7.89% | 354B | |
| +15.66% | 328B | |
| +0.24% | 277B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +4.23% | 164B | |
| -1.70% | 164B | |
| -1.31% | 122B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study
